Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported Q2 EPS of ($0.45), $0.03 worse than the analyst estimate of ($0.42).

For earnings history and earnings-related data on Ultragenyx Pharmaceutical Inc. (RARE) click here.